Having worked in the field of antibody development field for many years, Creative Biolabs gained a wealth of experience in application-specific antibody development. With professional scientists and advanced technology, now we can provide a full range of in vitro diagnostic (IVD) antibody development services targeting different biomarkers to promote our customer’s projects. Here, we introduce our IVD antibody development services for Rubeola.
Introduction of Rubeola
Rubeola virus, also known as measles virus, is a single-stranded, negative-sense RNA virus in the genus Morbillivirus of the family Paramyxoviridae. Humans are the only natural host of this highly contagious virus. As an airborne pathogen, measles virus can be transmitted by inhalation of respiratory droplets that disperse within minutes and smaller aerosols that can remain suspended for several hours. Moreover, it can also be transmitted through direct contact with infected secretions, but it does not survive long on fomites. It is inactivated by heat and UV radiation within a few hours. Importantly, the prodromal phase of measles involves sneezing and coughing, which enhance the transmission of the virus. And the incubation period is approximately 10 days to the onset of fever and 14 days to the onset of rash. Clinical signs of measles include a generalized maculopapular (non-vesicular) skin rash and fever above 38.3°C (101°F) accompanied by a cough, coryza (or rhinitis) and/or conjunctivitis.
Fig.1 Schematic representation of measles virus and its genome.1
Correlation of Rubeola and Childhood
Measles is thought to be an important cause of childhood morbidity and mortality in high-income and low-income countries. According to the World Health Organization (WHO), millions of children died of measles every year in pre-vaccine phase, accounting for 5% of all under-five mortalities. Infants become susceptible to measles virus infection when passively acquired maternal antibody is lost. What’s more, infants born to women with vaccine-induced immunity become susceptible to measles at a younger age than those born to women with naturally acquired immunity. And the average age at which people contract measles depends on the rate of decline of protective maternal antibodies, the amount of contact with infected people, and the level of measles vaccine coverage.
Fig.2 Measles virus life cycle.2
In recent years, IVD technologies are undergoing rapid development. Antibody-based immunoassays have been the most commonly used IVD tools and are the fastest developing technologies for disease screening. With years of experience and advanced platform, Creative Biolabs provides high-quality IVD antibody development services against rubeola to worldwide customers.
In addition, Creative Biolabs provides one-stop diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, validation, and production. For more detailed information, please feel free to contact us or directly send us an inquiry.
References
For Research Use Only.
